EMEA-001710-PIP04-17-M03
Key facts
Invented name |
Zeposia
|
Active substance |
Ozanimod (hydrochloride)
|
Therapeutic area |
Gastroentology-Hepatology
|
Decision number |
P/0131/2022
|
PIP number |
EMEA-001710-PIP04-17-M03
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of Crohn's disease
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|